Empiric therapy for secondary peritonitis: A pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation

Clinical Therapeutics

Volumn 29, Issue 5, 2007, Pages 889-899

  Eagye, Kathryn J ^a   Kuti, Joseph L ^a   Dowzicky, Michael ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

Monte Carlo simulation; pharmacodynamic profiling; secondary peritonitis; tigecycline

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; DRUG EFFICACY; EMPIRICAL RESEARCH; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PERITONITIS; PROTEUS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STEADY STATE; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONTE CARLO METHOD; PERITONITIS;

EID: 34547697321     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.05.018     Document Type: Article

References (39)

1. Barie P.S. Serious intra-abdominal infections. Curr Opin Crit Care 7 (2001) 263-267
2. McClean K.L., Sheehan G.J., and Harding G.K. Intraabdominal infection: A review. Clin Infect Dis. 19 (1994) 100-116
3. Marshall J.C., and Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med. 31 (2003) 2228-2237
4. Onderdonk A.B., Cisneros R.L., Finberg R., et al. Animal model system for studying virulence of and host response to Bacteroides fragilis. Rev Infect Dis. 12 Suppl 2 (1990) S169-S177
5. Montravers P., Gauzit R., Muller C., et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 23 (1996) 486-494
6. Falagas M.E., Barefoot L., Griffith J., et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis. 15 (1996) 913-921
7. Cattan P., Yin D.D., Sarfati E., et al. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis. 21 (2002) 787-793
8. Krobot K., Yin D., Zhang Q., et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 23 (2004) 682-687
9. Sturkenboom M.C., Goettsch W.G., Picelli G., et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol. 60 (2005) 438-443
10. Solomkin J.S., Mazuski J.E., Baron E.J., et al., Infectious Diseases Society of America. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 37 (2003) 997-1005
11. Wong P.F., Gilliam A.D., Kumar S., et al. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev. 2 (2005) CD004539
12. Zhanel G.G., Homenuik K., Nichol K., et al. The glycylcyclines: A comparative review with the tetracyclines. Drugs 64 (2004) 63-88
13. Guay D.R. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 24 (2004) 58-68
14. quiz 11-12. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26 (1998) 1-10
15. Kotapati S., Kuti J.L., and Nicolau D.P. Pharmacodynamic modeling of betalactam antibiotics for the empiric treatment of secondary peritonitis: A report from the OPTAMA program. Surg Infect (Larchmt) 6 (2005) 297-304
16. Eagye K.J., Kuti J.L., and Nicolau D.P. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect (Larchmt) 8 (2007) 215-226
17. Hoban D.J., Bouchillon S.K., Johnson B..M., et al. In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis. 52 (2005) 215-227
18. Fedler K.A., Biedenbach D.J., and Jones R.N. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: Report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis. 56 (2006) 427-436
19. Van Wart S.A., Owen J.S., Ludwig E.A., et al. Population pharmacokinetics of tigecycline in patients with com plicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 50 (2006) 3701-3707
20. DeRyke C.A., Kuti J.L., and Nicolau D.P. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 27 (2007) 333-342
21. Solomkin J.S., Yellin A.E., Rotstein O.D., et al., Protocol 017 Study Group. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trial. Ann Surg. 237 (2003) 235-245
22. Mouton J.W., Dudley M.N., Cars O., et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother 55 (2005) 601-607
23. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis. 27 (1998) 10-22
24. Abstract. Walker R., Andes D., Conklin J., et al. Pharmacodynamic activities of meropenem in an animal infection model. Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando) (1994), American Society for Microbiology, Washington, DC 147
25. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynam ics. J Antimicrob Chemother. 46 (2000) 669-683
26. Craig W.A., Andes D.R., Ambrose P.G., et al. In vivo pharmacodynamic activity of gatifloxacin, levofloxacin, and moxifloxacin against Staphylococcus aureus with reduced susceptibility to fluoroquinolones. Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005), American Society for Microbiology, Washington, DC
27. Meagher A.K., Ambrose P.G., Grasela T.H., and Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 52 (2005) 165-171
28. Jones R.N., Craig W.A., Ambrose P.G., et al. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone di ameter regression scattergrams for 9 beta-lactams: Adjustments of breakpoints for strains producing extended spectrum beta-lactamases. Diagn Microbiol Infect Dis. 52 (2005) 235-246
29. Newcombe R.G. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med. 17 (1998) 857-872
30. Drusano G.L., Preston S.L., Hardalo C., et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45 (2001) 13-22
31. quiz 993-995. Bradley J.S., Dudley M.N., and Drusano G.L. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 22 (2003) 982-992
32. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 48 (2004) 2464-2470
33. Kuti J.L., Ong C., Lo M., et al. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 28 (2006) 62-68
34. Barie P.S., Christou N.V., Dellinger E.P., et al. Pathogenicity of the enterococcus in surgical infections. Ann Surg. 212 (1990) 155-159
35. Rohrborn A., Wacha H., Schoffel U., et al. Coverage of enterococci in community acquired secondary peritonitis: Results of a randomized trial. Surg Infect (Larchmt) 1 (2000) 95-107
36. Sitges-Serra A., Lopez M.J., Girvent M., et al. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg. 89 (2002) 361-367
37. Primaxin [package insert] (2001), Merck & Co, Inc, Whitehouse Station, NJ
38. Babinchak T., Ellis-Grosse E., Dartois N., et al., Tigecycline 301 Study Group and the Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis. 41 Suppl 5 (2005) 5354-5367
39. Kuti J.L., and Nicolau D.P. Making the most of surveillance studies: Summary of the OPTAMA Program. Diagn Microbiol Infect Dis. 53 (2005) 281-287